Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Novant Health Cancer Specialists-Matthews
mi
from
Matthews, NC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Novant Health Cancer Specialists-Matthews
mi
from
Matthews, NC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Lake Norman Hematology Oncology Specialists-Mooresville
mi
from
Mooresville, NC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Lake Norman Hematology Oncology Specialists-Mooresville
mi
from
Mooresville, NC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Columbus NCI Community Oncology Research Program
mi
from
Columbus, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Columbus NCI Community Oncology Research Program
mi
from
Columbus, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Delaware Radiation Oncology
mi
from
Delaware, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Delaware Radiation Oncology
mi
from
Delaware, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Lancaster Radiation Oncology
mi
from
Lancaster, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Lancaster Radiation Oncology
mi
from
Lancaster, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Newark Radiation Oncology
mi
from
Newark, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Newark Radiation Oncology
mi
from
Newark, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Spartanburg Medical Center
mi
from
Spartanburg, SC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Spartanburg Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
M D Anderson Cancer Center
mi
from
Houston, TX
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Methodist Hospital System
mi
from
Houston, TX
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
EvergreenHealth Medical Center
mi
from
Kirkland, WA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
EvergreenHealth Medical Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Status: Enrolling
Updated:  11/24/2017
NYU School of Medicine
mi
from
New York, NY
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Status: Enrolling
Updated: 11/24/2017
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Status: Enrolling
Updated:  11/27/2017
Bastyr University
mi
from
Kenmore, WA
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Status: Enrolling
Updated: 11/27/2017
Bastyr University
mi
from
Kenmore, WA
Click here to add this to my saved trials
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  11/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 11/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Florida Cancer Specialists - Tampa (Dr. MLK Blvd)
mi
from
Tampa, FL
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Florida Cancer Specialists - Tampa (Dr. MLK Blvd)
mi
from
Tampa, FL
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Texas Oncology - Baylor Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/27/2017
UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy
mi
from
Leuven,
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/27/2017
UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy
mi
from
Leuven,
Click here to add this to my saved trials
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab
Status: Enrolling
Updated:  11/28/2017
Santa Clara Valley Medical Center
mi
from
San Jose, CA
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab
Status: Enrolling
Updated: 11/28/2017
Santa Clara Valley Medical Center
mi
from
San Jose, CA
Click here to add this to my saved trials
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab
Status: Enrolling
Updated:  11/28/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab
Status: Enrolling
Updated: 11/28/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated:  11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated: 11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer
Status: Enrolling
Updated:  11/29/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer
Status: Enrolling
Updated: 11/29/2017
University of Minnesota Children's Hospital - Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Breast Tumor Oxygenation During Exercise
Breast Tumor Oxygenation During Exercise
Status: Enrolling
Updated:  11/30/2017
Beckman Laser Institute Medical clinic
mi
from
Irvine, CA
Breast Tumor Oxygenation During Exercise
Breast Tumor Oxygenation During Exercise
Status: Enrolling
Updated: 11/30/2017
Beckman Laser Institute Medical clinic
mi
from
Irvine, CA
Click here to add this to my saved trials
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/30/2017
Ohio State University
mi
from
Columbus, OH
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/30/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer
Status: Enrolling
Updated:  12/3/2017
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer
Status: Enrolling
Updated: 12/3/2017
Kimmel Cancer Center at Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer
Status: Enrolling
Updated:  12/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer
Status: Enrolling
Updated: 12/4/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials